Immunotherapy Study for Surgically Resected Pancreatic Cancer

Trial ID or NCT#

NCT01072981

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.

Official Title

A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

George A Fisher
George A Fisher
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine, Emeritus

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov